BioNexus Gene Lab Corp. (BGLC) 宣布一项关键人事任命，Muthu Meyyappan博士已正式加入其子公司Fidelion Diagnostics，担任首席商务官。在这一新职位上，Meyyappan博士将承担起领导Vitaguard™ MRD（微小残留病灶）检测平台全球商业化战略的重任。此次任命旨在加速该前沿诊断技术的市场推广与应用，扩大其全球影响力。
BioNexus Gene Lab Corp. (BGLC) 宣布一项关键人事任命，Muthu Meyyappan博士已正式加入其子公司Fidelion Diagnostics，担任首席商务官。在这一新职位上，Meyyappan博士将承担起领导Vitaguard™ MRD（微小残留病灶）检测平台全球商业化战略的重任。此次任命旨在加速该前沿诊断技术的市场推广与应用，扩大其全球影响力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.